Your browser is no longer supported. Please, upgrade your browser.
Settings
CDMOP Avid Bioservices, Inc. daily Stock Chart
CDMOP [NASD]
Avid Bioservices, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own7.06% Shs Outstand44.01M Perf Week0.80%
Market Cap1.10B Forward P/E- EPS next Y- Insider Trans- Shs Float44.01M Perf Month-0.26%
Income- PEG- EPS next Q- Inst Own0.72% Short Float0.01% Perf Quarter2.32%
Sales64.58M P/S17.11 EPS this Y- Inst Trans- Short Ratio4.54 Perf Half Y5.68%
Book/sh0.70 P/B36.06 EPS next Y- ROA- Target Price- Perf Year13.27%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range20.62 - 27.00 Perf YTD2.87%
Dividend2.62 P/FCF- EPS past 5Y- ROI- 52W High-7.04% Beta-
Dividend %10.44% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low21.73% ATR0.16
Employees319 Current Ratio- Sales Q/Q-36.50% Oper. Margin- RSI (14)52.50 Volatility0.26% 0.47%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.50 Prev Close25.10
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.41K Price25.10
Recom- SMA200.28% SMA500.46% SMA2005.27% Volume701 Change0.00%
May-08-18 08:05AM  Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences GlobeNewswire
Apr-24-18 08:05AM  Avid Bioservices Provides Update on Ongoing Expansion of Process Development Capabilities and Laboratory Infrastructure GlobeNewswire
Apr-09-18 08:05AM  Avid Bioservices to Participate at INTERPHEX 2018 GlobeNewswire
Mar-22-18 08:05AM  Avid Bioservices Receives Six 2018 CMO Leadership Awards GlobeNewswire
Mar-13-18 08:05AM  Avid Bioservices to Participate at Upcoming CDMO Industry Conferences GlobeNewswire
Mar-12-18 04:05PM  Avid Bioservices Reports Financial Results for Third Quarter of Fiscal Year 2018 and Recent Developments GlobeNewswire
Mar-07-18 04:05PM  Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
Mar-06-18 08:05AM  Avid Bioservices to Present at the 30th Annual ROTH Conference GlobeNewswire
Mar-05-18 08:05AM  Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018 GlobeNewswire
Mar-01-18 08:05AM  Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimers Disease Candidate GlobeNewswire
Feb-26-18 08:05AM  Avid Bioservices Announces Resignation of Chief Financial Officer GlobeNewswire
Feb-21-18 08:05AM  Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences GlobeNewswire
Feb-20-18 04:05PM  Avid Bioservices Announces Closing of Public Offering of Common Stock GlobeNewswire
Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.